These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6729558)

  • 1. Objective response in amyloidosis treated with intermittent chemotherapy.
    Farhangi M; Thakur VM; Durham JB
    South Med J; 1984 Jun; 77(6):775-7. PubMed ID: 6729558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The successful treatment of primary amyloidosis with intermittent chemotherapy.
    Bradstock K; Clancy R; Uther J; Basten A; Richards J
    Aust N Z J Med; 1978 Apr; 8(2):176-9. PubMed ID: 277166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature.
    Gertz MA; Kyle RA
    Mayo Clin Proc; 1986 Mar; 61(3):218-23. PubMed ID: 3945122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
    Kyle RA; Greipp PR; Garton JP; Gertz MA
    Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of primary amyloidosis with dimethylsulfoxide and cytoreductive chemotherapy.
    Shibuya T; Murakawa M; Tsuda Y; Harada M
    Intern Med; 1992 Apr; 31(4):544-8. PubMed ID: 1633367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
    Schattner A; Varon D; Green L; Hurwitz N; Bentwich Z
    Am J Med; 1989 Mar; 86(3):347-8. PubMed ID: 2919619
    [No Abstract]   [Full Text] [Related]  

  • 7. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
    Camoriano JK; Greipp PR; Bayer GK; Bowie EJ
    N Engl J Med; 1987 Apr; 316(18):1133-5. PubMed ID: 3574359
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
    Benson MD
    Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma). A demonstration of the course using melphalan-prednisone therapy with a 3 years remission].
    Jänner M; Lippert HD; Stolzenbach G
    Z Hautkr; 1977 Aug; 52(16):873-40. PubMed ID: 408988
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
    Kyle RA; Greipp PR
    Blood; 1978 Oct; 52(4):818-27. PubMed ID: 356916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
    Levin M; Chokas W
    N Engl J Med; 1987 Oct; 317(18):1155-6. PubMed ID: 3657882
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of primary amyloidosis with melphalan and prednisone.
    Schwartz RS; Cohen JR; Schrier SL
    Arch Intern Med; 1979 Oct; 139(10):1144-7. PubMed ID: 485747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Falk RH; Berk JL; Dember LM; Finn KT; Skinner M
    Br J Haematol; 2002 Jun; 117(4):886-9. PubMed ID: 12060126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloidosis of immunoglobulin origin: useful treatment?
    Brown MP; Walls RS
    Med J Aust; 1990 Jan; 152(2):95-7. PubMed ID: 2104951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
    Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
    J Clin Oncol; 1999 Jan; 17(1):262-7. PubMed ID: 10458241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy for primary amyloidosis reconsidered.
    Cohen HJ
    Ann Intern Med; 1978 Oct; 89(4):572-3. PubMed ID: 697241
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G; Wiater E; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy.
    Corkery J; Bern MM; Tullis JL
    Lancet; 1978 Aug; 2(8086):425-6. PubMed ID: 79787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.